Why carry out this study?

Persistence for biologic therapy in the treatment of moderate-to-severe psoriasis is unsatisfactory.

This patient-level registry study from Sweden characterized the persistence with individual biologics and the changes in persistence over time.

What was learned from the study?

The results of this study may aid in clinical decision-making when choosing a biological therapy for patients with psoriasis by contributing important evidence on the differential persistence over time for each biologic to the body of evidence on persistence of biologic therapy, which usually only focusses on persistence at a given point in time.

The findings may inform clinical decision-making based on evidence on the differential persistence over time for each biologic.